

- **Name:** Hyunseok Kang
 - **Current Position & Affiliation:** Professor / University of California, San Francisco
 - **Country:** USA
-

• **Educational Background:**

MD, Yonsei University College of Medicine, Seoul, Korea

MPH, Yonsei University Graduate School of Public Health, Seoul, Korea

• **Professional Experience:**

Internal Medicine Residency, St.Luke's-Roosevelt Hospital Center/Columbia University, New York, NY

Hematology/Oncology Fellowship, Emory University, Atlanta, GA

Instructor/Assistant Professor, Johns Hopkins University, Baltimore, MD

Associate Professor, University of California, San Francisco

• **Professional Organizations:**

Fellow of American College of Physicians (FACP)

Member of American Society of Clinical Oncology (Program Committee), American Association for Cancer Research, Head and Neck Core Committee in NRG Oncology, Society for Immunotherapy of Cancer (Award Review Committee), American Thyroid Association (Clinical Affairs Committee), International Thyroid Oncology Group (Protocol Committee), American Head and Neck Society

Associate Editor for Head and Neck, Cancer Medicine and Journal Watch Hematology Oncology

• **Main Scientific Publications:**

1. Kurzrock R, Bowles DW, **Kang H**, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C. Targeted therapy for advance salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. *Ann Oncol* 2020; 31(3):412-421
2. Park JC, Durbeck J, Boudadi K, Ho WJ, **Kang H**. The efficacy of anti-PD-1 immune checkpoint inhibitor in nasopharyngeal carcinoma. *Oral Oncol.* 2020; 108:104935.
3. Wirth LJ, Sherman E, Robinson B, Solomon B, **Kang H**, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW,

- Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. *N Engl J Med*. 2020; 383(9):825-835.
4. Park JC, Ashok A, Liu C, **Kang H**. Real world experience of NTRK fusion positive thyroid cancer. *JCO Precis Oncol* 2022;6:e2100442
 5. Rodriguez CP*, **Kang H***, Geiger JL*, Burtneess B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. Clinical trial development in TP53 mutated locally advanced and recurrent/metastatic head and neck squamous cell carcinoma. *J Nat Cancer Inst* 2022; 114:1619-1627 *Equal contribution
 6. Ho AL, Foster NR, Zoroufy AJ, Campbell JD, Worden F, Price K, Adkins D, Bowles DW, **Kang H**, Burtneess B, Sherman E, Morton R, Morris LGT, Nadeem Z, Katabi N, Munster P, Schwartz GK. A phase II study of enzalutamide for patients with androgen receptor positive salivary gland cancers (Alliance A091404). *J Clin Oncol* 2022; 40:4240-4249
 7. Subbiah V, Wolf J, Konda B, **Kang H**, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K, Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumor-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumors other than lung or thyroid tumors (LIBRETTO-001): a phase 1/2 open-label, basket trial. *Lancet Oncol* 2022;23:1261-1273
 8. Hanna GJ, Ahn MJ, Muzaffar J, Keam B, Bowles DW, Wong DJ, Ho AL, Kim SB, Worden F, Yun T, Zhao Y, Van Tornout J, Gonlan M, **Kang H**. A Phase 2 Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma. *Clin Cancer Res* 2023; 29(22):4555-4563
 9. Ferrarotto R, Swiecicki PL, Zandberg DP, Baiocchi RA, Wesolowski R, Rodriguez CP, McKean M, **Kang H**, Monga V, Nath R, Palmisiano N, Babbar N, Sun W, Hanna GJ. PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study. *Oral Oncol* 2024;149:106634
 10. Raez LE, **Kang H**, Ohe Y, Khanal M, Han Y, Szymczak S, Barker SS, Giligan AM. Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in phase I/II LIBRETTO-001 trial. *ESMO Open* 2024;9(5):103444
 11. Cui Z, **Kang H**, Li H, Lee ED, Lee YS, Peterson CN, Long SR, Grandis JR, Johnson DE. CYLD alterations are associated with metastasis and poor prognosis in human papilloma virus-positive head and neck cancer. *Head Neck* 2025; 47(2):606-614
 12. Chin A, Lindsay S, Bergsland EK, **Kang H**. Withdrawal pain following patients discontinuing Trk inhibitors. *J Oncol Pharm Pract* 2025;31(1):147-150